People | October 13, 2025
Relmada therapeutics appoints Dr. Max Kates to propel NDV-01 toward phase 3
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
Liothyronine tablets will be manufactured at Zydus' plant in Ahmedabad SEZ
All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety
Bain Capital and Cinven will each retain a minority stake, reflecting their ongoing confidence in STADA’s future growth
VYVGART was well tolerated, with a safety profile consistent with prior studies in AChR-Ab seropositive gMG and other indications
All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone
The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study
This is the group’s first NoC approval in Canada
Subscribe To Our Newsletter & Stay Updated
